Sector Gamma As Lowers stake in Baxter International Inc (BAX)

Baxter International Inc (BAX) : Sector Gamma As reduced its stake in Baxter International Inc by 11.4% during the most recent quarter end. The investment management company now holds a total of 1,078,943 shares of Baxter International Inc which is valued at $52,425,840 after selling 138,887 shares in Baxter International Inc , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Baxter International Inc makes up approximately 10.03% of Sector Gamma As’s portfolio.

Other Hedge Funds, Including , Kernodle Katon Asset Management Group sold out all of its stake in BAX during the most recent quarter. The investment firm sold 55 shares of BAX which is valued $2,672.Cetera Advisor Networks reduced its stake in BAX by selling 3,695 shares or 13.07% in the most recent quarter. The Hedge Fund company now holds 24,578 shares of BAX which is valued at $1,194,245. Baxter International Inc makes up approx 0.07% of Cetera Advisor Networks’s portfolio.Sandy Spring Bank reduced its stake in BAX by selling 1,400 shares or 2.6% in the most recent quarter. The Hedge Fund company now holds 52,439 shares of BAX which is valued at $2,516,023. Baxter International Inc makes up approx 0.28% of Sandy Spring Bank’s portfolio.Concert Wealth Management boosted its stake in BAX in the latest quarter, The investment management firm added 2,454 additional shares and now holds a total of 15,882 shares of Baxter International Inc which is valued at $762,654. Baxter International Inc makes up approx 0.10% of Concert Wealth Management’s portfolio. Yhb Investment Advisors added BAX to its portfolio by purchasing 5,558 company shares during the most recent quarter which is valued at $257,447. Baxter International Inc makes up approx 0.05% of Yhb Investment Advisors’s portfolio.

Baxter International Inc (BAX) witnessed a volatile trading activity on Tuesday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $48.07 and reached the intraday high at $48.35. The bulls started the profit booking and pushed the shares to intraday low of $47.94. The trading session was marked by a volume range of 22,80,837 shares exchanging hands. The 52-week high of the shares is $49.485 and the 52-week low is $32.18. The market cap of the company stands at $26,096 M and there are 54,38,87,680 shares in public circulation.

On the company’s financial health, Baxter International Inc reported $0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.40. The company had revenue of $2585.00 million for the quarter, compared to analysts expectations of $2516.16 million. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 EPS.

Investors should note that on Jul 19, 2016, Baxter International Inc announced a cash dividend of $0.1300. The company’s management has announced Aug 31, 2016 as the ex-dividend date and fixed the record date on Sep 2, 2016. The payable date has been fixed on Oct 3, 2016.

Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Jul 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 50 from a previous price target of $47 .Baxter International Inc was Resumed by JP Morgan to “Neutral” on Jun 6, 2016.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *